| 79.79 0.41 (0.52%) | 06-20 13:19 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 95.25 | 1-year : | 111.25 |
| Resists | First : | 81.55 | Second : | 95.25 |
| Pivot price | 77.66  |
|||
| Supports | First : | 75.68 |
Second : | 72.05 |
| MAs | MA(5) : | 78.76  |
MA(20) : | 77.16 |
| MA(100) : | 63.19 |
MA(250) : | 54.72 |
|
| MACD | MACD : | 1.5 |
Signal : | 1.5 |
| %K %D | K(14,3) : | 69.8 |
D(3) : | 66 |
| RSI | RSI(14): 59.8 |
|||
| 52-week | High : | 81.55 | Low : | 36.93 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ SLNO ] has closed below upper band by 25.3%. Bollinger Bands are 33.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 79.66 - 80.14 | 80.14 - 80.6 |
| Low: | 75.79 - 76.35 | 76.35 - 76.89 |
| Close: | 78.51 - 79.35 | 79.35 - 80.15 |
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Fri, 20 Jun 2025
Piper Sandler Reaffirms Overweight Rating on Soleno (SLNO) Driven by Strong VYKAT XR Prospects - Insider Monkey
Fri, 20 Jun 2025
New Clinical Data Shows Promising Results for Prader-Willi Syndrome Treatment at Major Conference - Stock Titan
Wed, 21 May 2025
Rare Disease Leader Soleno Therapeutics Secures Speaking Slots at Major Healthcare Conferences - Stock Titan
Tue, 13 May 2025
Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ISPOR 2025 - Stock Titan
Sun, 11 May 2025
Is Soleno Therapeutics (SLNO) the Best Performing Healthcare Stock to Buy Now? - Yahoo Finance
Wed, 07 May 2025
Soleno Therapeutics Provides Update on U.S. Launch of - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 50 (M) |
| Shares Float | 38 (M) |
| Held by Insiders | 1.8 (%) |
| Held by Institutions | 112.2 (%) |
| Shares Short | 4,150 (K) |
| Shares Short P.Month | 5,010 (K) |
| EPS | -4.74 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.78 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -52.5 % |
| Return on Equity (ttm) | -105.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.02 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -89 (M) |
| Levered Free Cash Flow | -34 (M) |
| PE Ratio | -16.79 |
| PEG Ratio | 0 |
| Price to Book value | 16.61 |
| Price to Sales | 0 |
| Price to Cash Flow | -44.89 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|